Safety performance of rivaroxaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease
| Autor: | Abram Syrkin, A A Bykova, S A Suchkova, M I Chashkina, A Yu Suvorov, Z K Salpagarova, Denis Andreev, N L Kozlovskaya |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Renal function 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Rivaroxaban Internal medicine Atrial Fibrillation medicine Humans Prospective Studies 030212 general & internal medicine Prospective cohort study Stroke business.industry Warfarin Anticoagulants Atrial fibrillation medicine.disease Treatment Outcome Cardiology and Cardiovascular Medicine Stage 4 chronic kidney disease business Factor Xa Inhibitors Kidney disease medicine.drug |
| Zdroj: | Kardiologiia. 60:94-100 |
| ISSN: | 2412-5660 0022-9040 |
| Popis: | Aim To evaluate safety of using rivaroxaban in patients with stage 4 chronic kidney disease (CKD) or transient, stable decline of glomerular filtration rate (GFR) to 15–29 ml /min / 1.73 m2 in the presence of atrial fibrillation (AF).Material and methods This multicenter prospective, randomized study included patients admitted to cardiology departments from 2017 through 2019. Of 10 224 admitted patients 109 (3 %) patients with AF and stage 4 CKD or a stable decline of GFR to 15–29 ml /min / 1.73 m2 were randomized at 2:1 ratio to the rivaroxaban 15 mg /day (n=73) treatment group or to the warfarin treatment group (n=36). The primary endpoint was development of BARC and ISTH major, minor, and clinically relevant minor bleeding. Mean follow-up duration was 18 months.Results Patients receiving warfarin had a significantly higher incidence of BARC (n=26 (72.2 %) vs. n=31 (42.4 %), рConclusion The study provided evidence for a more beneficial safety profile of rivaroxaban compared to warfarin in patients with AF and advanced CKD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|